Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St futures tick higher after tech rout; Mideast, tariffs in focus
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, but set for weekly rise on Middle East escalation
- Meta’s new seller app hits eBay where it hurts most
- American Express down 2% in premarket trade after Q2 revenue miss offsets EPS beat
Lexicon Appoints Ivan H. Cheung to Board of Directors
November 20, 2024 4:05 PM ESTTHE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors.
Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth a growth investing platform within global asset manager TPG since September 2023.
I am honored to... More
